Phase 1 Study To Evaluate the Safety and Pharmacokinetics of Palbociclib (Ibrance?) in Combination with Irinotecan and Temozolomide in Pediatric Patients with Recurrent or Refractory Solid Tumors
Objective
Primary Objective(s):To estimate the MTD for the combination of palbociclib, TMZ, and IRN in children, adolescents, and young adults with recurrent or refractory solid tumors.